F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
01 11월 2021 - 9:00PM
F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage
biopharmaceutical company dedicated to developing next generation
immunotherapies to transform the lives of patients with cancer,
announced today that the Company will hold a conference call and
webcast on November 10, 2021, at 9:00 a.m. EST to review third
quarter 2021 financial results and provide a corporate update.
To access the call, participants may join via a live webcast on
the Investors & News section of the F-star Therapeutics
website, under Events and Presentations. To join by phone,
participants may dial the following numbers at least 10 minutes
prior to the start of the call:
US/Canada: |
1-833-471-0868 |
International: |
1-914-987-7751 |
United Kingdom: |
800 0288438 or 0203 1070289 |
A replay of the conference call will be available for 90 days
from the call and may be accessed in the Investors &
News/Events and Presentations section on the F-star Therapeutics
website.
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. (collectively with its subsidiaries,
“F-star” or the “Company”) is a clinical-stage biopharmaceutical
company dedicated to developing next generation immunotherapies to
transform the lives of patients with cancer. F-star is pioneering
the use of tetravalent (2+2) bispecific antibodies to create a
paradigm shift in cancer therapy. The Company has four
second-generation immuno-oncology therapeutics in the clinic, each
directed against some of the most promising IO targets in drug
development, including LAG-3 and CD137. F-star’s proprietary
antibody discovery platform is protected by an extensive
intellectual property estate. F-star has over 500 granted patents
and pending patent applications relating to its platform technology
and product pipeline. The Company has attracted multiple
partnerships with biopharma targeting the significant unmet needs
across several disease areas, including oncology, immunology, and
CNS.
For more information visit https://www.f-star.com/ and
follow us on LinkedIn and Twitter.
For further information, please contact:
For investor inquiriesLindsey
TrickettVP Investor Relations & Communications+1 240
543 7970lindsey.trickett@fstar.com
For media inquiriesHelen
ShikShik Communications LLC+1
617-510-4373helen@shikcommunications.com
F star Therapeutics (NASDAQ:FSTX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
F star Therapeutics (NASDAQ:FSTX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
F star Therapeutics Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More News Articles